Tavapadon

AbbVie's phase 3 TEMPO-1 trial of tavapadon, a D1/D5 dopamine receptor partial agonist, showed significant improvement in Parkinson's disease symptoms compared to placebo, meeting primary and secondary endpoints. Full results will support regulatory submissions and be presented at medical meetings.

Tavapadon, a dopamine agonist, significantly improved motor function in early-stage Parkinson’s patients in the Phase 3 TEMPO-1 trial. Both 5 mg and 15 mg doses showed significant decreases in MDS-UPDRS scores compared to placebo, indicating improved motor function. The therapy's safety profile was consistent with previous trials, with most adverse events being mild to moderate. Data from TEMPO-2 and TEMPO-3 trials further support tavapadon's potential as a new treatment option for Parkinson’s disease.

AbbVie announced positive results from the phase III TEMPO-1 study, showing tavapadon significantly improved early Parkinson’s disease symptoms in 26 weeks. The drug met primary and secondary endpoints, with a consistent safety profile. AbbVie plans to seek regulatory approval using these data.

AbbVie's Phase 3 TEMPO-1 trial for tavapadon, a D1/D5 dopamine receptor partial agonist, met primary endpoint in early Parkinson’s disease. The trial showed significant reduction in MDS-UPDRS scores at week 26, with safety profile consistent with previous studies. Full results will support regulatory submissions, with TEMPO-2 topline results expected by year-end.

Leerink Partners' David Risinger maintains a Hold rating on AbbVie (ABBV) stock, citing positive Phase 3 tavapadon trial results but cautious about sales projections, remaining trials, and market competition.

J&J's Talvey shows promise in multiple myeloma trials; FDA advisory committee votes against cancer immunotherapy use in certain digestive tract cancers; AbbVie's acquisition of Cerevel Therapeutics yields positive Parkinson's drug results; Roche's Gazyva succeeds in lupus nephritis Phase 3 study; Biogen terminates agreement with Sage Therapeutics over failed essential tremor drug; Enanta Pharmaceuticals' EDP-323 shows rapid antiviral effect against RSV.

AbbVie's tavapadon met primary efficacy endpoint in Phase III TEMPO-1 trial, showing significant improvements in motor and non-motor symptoms in early-stage Parkinson’s patients. The 5-mg dose improved MDS-UPDRS parts II and III scores by 9.7 points, while the 15-mg dose improved by 10.2 points, both significantly better than placebo. Tavapadon was well-tolerated, with most side effects mild or moderate. AbbVie plans to present findings at a medical congress and use data for regulatory filing.

AbbVie's tavapadon, acquired from Cerevel Therapeutics, significantly reduced Parkinson's disease burden in Phase III TEMPO-1 trial, outperforming placebo in both 5mg and 15mg doses. The drug targets dopamine D1 and D5 receptors, potentially generating $673m by 2030 if approved.

AbbVie’s tavapadon, acquired from Cerevel Therapeutics, significantly reduced Parkinson’s disease burden in Phase III TEMPO-1 trial, outperforming placebo in both 5mg and 15mg doses. The drug also improved motor aspects of daily living and maintained a consistent safety profile. Tavapadon is an oral dopamine receptor agonist targeting D1 and D5 receptors, potentially generating $673m by 2030 if approved.

AbbVie's phase 3 TEMPO-1 trial showed tavapadon, a monotherapy for Parkinson disease, significantly improved MDS-UPDRS scores at week 26. The study involved 529 PD patients aged 40-80, with both 5 mg and 15 mg doses outperforming placebo. Secondary endpoints and safety profile were consistent with prior trials, supporting tavapadon's potential in PD treatment.